Low-Dose Bevacizumab-But What About Long-term Results?

JAMA Ophthalmol. 2022 Mar 1;140(3):287-288. doi: 10.1001/jamaophthalmol.2021.5864.
No abstract available

Publication types

  • Comment

MeSH terms

  • Angiogenesis Inhibitors / adverse effects
  • Bevacizumab / adverse effects
  • Humans
  • Infant, Newborn
  • Retinopathy of Prematurity* / drug therapy
  • Vascular Endothelial Growth Factor A

Substances

  • Angiogenesis Inhibitors
  • Vascular Endothelial Growth Factor A
  • Bevacizumab